Sumitomo Pharma has registered the issuance of new shares with an upper limit of 60,000,000 shares and 140 billion yen, planning to secure funds to promote the growth strategy ‘Boost 2028.’<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4506-20260302-01.pdf","jir_short_summary":"Sumitomo Pharma has registered the issuance of new shares with an upper limit of 60,000,000 shares and 140 billion yen, planning to secure funds to promote the growth strategy 'Boost 2028.'","jir_summary":"### Overview of Capital Policy\nAt the board meeting held on March 2, 2026, Sumitomo Pharma Co., Ltd. resolved to register the issuance of new shares and submitted the registration documents to the Kanto Local Finance Bureau. The number of shares to be issued is up to 60,000,000 shares, with an upper limit of 140 billion yen in the amount to be raised. The issuance period is scheduled from March 10, 2026, to March 9, 2027. The procured funds are planned to be allocated to research and development expenses, capital investment expenses, investment and loan expenses, working capital, and repayment of interest-bearing debt.\n\n### Impact on Shareholders and Future Outlook\nAlthough this public offering is expected to dilute Sumitomo Chemical's voting rights ratio, the company will remain a consolidated subsidiary of Sumitomo Chemical. In addition, in conjunction with refinancing borrowings, the company aims to refinance loans without Sumitomo Chemical\u2019s debt guarantees. Furthermore, as this capital increase will strengthen capital exceeding the capital-equivalent amount of hybrid bonds, no issuance of refinancing securities other than these shares will be undertaken, and early redemption is planned on the first optional redemption date. Through these measures, the company aims to enhance corporate value in the medium to long term and promote the growth strategy 'Boost 2028.'","jir_financial_highlights":"Planned Number of Shares to be Issued: Up to 60,000,000 shares (Unknown)\nPlanned Amount to be Raised: Up to 140 billion yen (Unknown)\nPlanned Issuance Period: From March 10, 2026 to March 9, 2027 (Unknown)","jir_category":"","jir_hashtags":"#SumitomoPharmaCoLtd, #CapitalPolicy, #NewShareIssuance, #JapaneseStocks","jir_key_figures":"Planned Number of Shares to be Issued: Up to 60,000,000 shares\nPlanned Amount to be Raised: Up to 140 billion yen\nPlanned Issuance Period: From March 10, 2026 to March 9, 2027","jir_meta_title":"Sumitomo Pharma Registers New Share Issuance to Raise Up to 140 Billion Yen \u2013 Cap at 60,000,000 Shares","jir_meta_description":"Sumitomo Pharma Co., Ltd. has registered the issuance of new shares with an upper limit of 60,000,000 shares and 140 billion yen, securing funds to advance the growth strategy 'Boost 2028.'","jir_og_title":"Sumitomo Pharma Announces New Share Issuance to Raise Up to 140 Billion Yen","jir_og_description":"Sumitomo Pharma has completed registration for new share issuance, planning to issue up to 60,000,000 shares to fund the growth strategy 'Boost 2028.'","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-32740","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n